Immune related adverse events and treatment discontinuation in patients older and younger than 75 years with advanced melanoma receiving nivolumab or pembrolizumab
Doran Ksienski, Pauline T. Truong, Nicole S. Croteau, Angela Chan, Eric Sonke, Tiffany Patterson, Melissa Clarkson, Samuel Hackett, Mary Lesperance
Topics & Concepts
MedicineDiscontinuationInternal medicineNivolumabAdverse effectHazard ratioIncidence (geometry)PembrolizumabCohortProportional hazards modelLogistic regressionRetrospective cohort studyCancerImmunotherapyConfidence intervalOpticsPhysicsCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy research